Evidence map›Paper›PMID 41114278›Full record

ArticleGynecologic oncology reports2025

Adrenal insufficiency after megestrol acetate for fertility-sparing treatment of endometrial cancer.

Lauren Clarfield, Laura Diamond, Soyoun Rachel Kim, Shima Deljoomanesh, Nashwah Taha, Shereen Ezzat, Eleni Dimaraki, Sarah E Ferguson

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lauren ClarfieldDepartment of Obstetrics and Gynaecology, University of Toronto, 123 Edward StreetSuite 1200, Toronto, Ontario M5G 1E2, Canada.
Laura DiamondDepartment of Obstetrics and Gynaecology, University of Toronto, 123 Edward StreetSuite 1200, Toronto, Ontario M5G 1E2, Canada.
Soyoun Rachel KimDepartment of Obstetrics and Gynaecology, University of Toronto, 123 Edward StreetSuite 1200, Toronto, Ontario M5G 1E2, Canada.
Shima DeljoomaneshDivision of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Princess Margaret Cancer Centre (University Health Network)/Sinai Health System, 190 Elizabeth St, Toronto, ON M5G 2C4, Canada.
Nashwah TahaDivision of Endocrinology and Metabolism, Scarborough Health Network, University of Toronto, 4040 Finch Avenue East, Scarborough, ON M1S 4V5, Canada.
Shereen EzzatEndocrine Oncology Site Group, University Health Network, University of Toronto, 190 Elizabeth St, Toronto, ON M5G 2C4, Canada.
Eleni DimarakiDivision of Endocrinology and Metabolism, Women's College Hospital, 76 Grenville St, Toronto, ON M5S 1B2, Canada.
Sarah E FergusonDepartment of Obstetrics and Gynaecology, University of Toronto, 123 Edward StreetSuite 1200, Toronto, Ontario M5G 1E2, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

•AI is a rare yet potentially life-threatening side effect of MA when used for fertility sparing for EC/AH.•The presentation of AI is highly variable and clinicians should employ a low threshold for investigations.•AI can occur while on MA therapy or after abrupt withdrawal; MA should be tapered upon discontinuation.•Patients on MA may require stress dosing at times of surgery/procedures or acute illness.•Consider progestin IUD as a first line therapy, especially in patients with metabolic comorbidities.

Identifiers

PMID41114278
PMCPMC12529359

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.